JOP20190152A1 - مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة - Google Patents

مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة

Info

Publication number
JOP20190152A1
JOP20190152A1 JOP/2019/0152A JOP20190152A JOP20190152A1 JO P20190152 A1 JOP20190152 A1 JO P20190152A1 JO P20190152 A JOP20190152 A JO P20190152A JO P20190152 A1 JOP20190152 A1 JO P20190152A1
Authority
JO
Jordan
Prior art keywords
activin
myostatin
treatment
obesity
receptor antagonists
Prior art date
Application number
JOP/2019/0152A
Other languages
English (en)
Inventor
Tania Silvia Garito
Marjorie Zakaria
Ronenn Roubenoff
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of JOP20190152A1 publication Critical patent/JOP20190152A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)

Abstract

يتعلق الاختراع الحالي بمضادات ميوستاتين أو آكتيفين أو مضادات مستقبل للاستخدام في تحسين تركيبة الجسم، مثلا، لعلاج البدانة المركزية، السمنة أو حالة زيادة الوزن والأمراض المصاحبة ذات الصلة. يتعلق الاختراع الحالي بمضادات ميوستاتين أو آكتيفين أو مضادات مستقبل لعلاج السكري من النوع II بواسطة تحسين التحكم في سكر الدم، تحديدا بواسطة زيادة حساسية الإنسولين. الشكل 1
JOP/2019/0152A 2016-12-21 2017-06-16 مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة JOP20190152A1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662437097P 2016-12-21 2016-12-21

Publications (1)

Publication Number Publication Date
JOP20190152A1 true JOP20190152A1 (ar) 2019-06-20

Family

ID=60972283

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0152A JOP20190152A1 (ar) 2016-12-21 2017-06-16 مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة

Country Status (24)

Country Link
US (2) US20190345251A1 (ar)
EP (2) EP3558361B1 (ar)
JP (2) JP7280825B2 (ar)
KR (2) KR20190097138A (ar)
CN (2) CN118105478A (ar)
AU (1) AU2017380844B2 (ar)
BR (1) BR112019012661A2 (ar)
CA (1) CA3042965A1 (ar)
CL (1) CL2019001683A1 (ar)
DK (1) DK3558361T3 (ar)
ES (1) ES3048908T3 (ar)
FI (1) FI3558361T3 (ar)
HR (1) HRP20251338T1 (ar)
IL (2) IL327136A (ar)
JO (1) JOP20190152A1 (ar)
LT (1) LT3558361T (ar)
MX (2) MX2019007581A (ar)
PH (1) PH12019501026A1 (ar)
PL (1) PL3558361T3 (ar)
PT (1) PT3558361T (ar)
RS (1) RS67393B1 (ar)
SI (1) SI3558361T1 (ar)
TW (2) TWI812606B (ar)
WO (1) WO2018116201A1 (ar)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10307480B2 (en) 2014-11-06 2019-06-04 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
PT3922645T (pt) 2015-09-15 2025-05-29 Scholar Rock Inc ¿anticorpos anti-pró-miostatina/miostatina latente e suas utilizações
CN115814077A (zh) 2016-01-08 2023-03-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
KR20210082548A (ko) 2016-06-13 2021-07-05 스칼러 락, 인크. 미오스타틴 억제제의 용도 및 조합 요법
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
US11155611B2 (en) 2017-01-06 2021-10-26 Scholar Rock, Inc. Compositions and methods for making and using anti-myostatin antibodies
GB201706857D0 (en) 2017-04-28 2017-06-14 Select Res Ltd Health risk prediction tools
JP7296408B2 (ja) 2018-06-18 2023-06-22 ヤンセン ファーマシューティカ エヌ．ベー． Ｍａｌｔ１阻害剤としてのピラゾール誘導体
MA55593A (fr) 2019-04-11 2022-02-16 Janssen Pharmaceutica Nv Cycles pyridine contenant des dérivés servant d'inhibiteurs de malt1
CA3153062A1 (en) 2019-09-03 2021-03-11 Novartis Ag Treatment of liver disease or disorder comprising actrii receptor antagonists
EP4142769A4 (en) 2020-04-28 2024-05-15 Acceleron Pharma Inc. ACTRII PROTEINS AND USE IN THE TREATMENT OF POSTCAPILLARY PULMONARY HYPERTENSION
US20240124541A1 (en) * 2021-04-12 2024-04-18 University of Florida Research Foundation, Incorprated Compositions and methods for treating obesity
JP2024524159A (ja) * 2021-06-23 2024-07-05 スカラー ロック インコーポレイテッド 代謝障害の治療における使用のためのｇｌｐ－１経路活性化剤と組み合わせたミオスタチン経路阻害剤
WO2023028606A1 (en) 2021-08-27 2023-03-02 Versanis Bio, Inc. Combination therapies
JP2025504453A (ja) * 2022-01-19 2025-02-12 バーサニス バイオ、インコーポレイテッド ＡｃｔＲＩＩ抗体治療
MX2025002126A (es) 2022-08-26 2025-04-02 Versanis Bio Inc Tratamientos con dosis unitarias fijas del anticuerpo actrii
AU2023413166A1 (en) 2022-12-22 2025-07-03 Scholar Rock, Inc. Selective and potent inhibitory antibodies of myostatin activation
AU2024317572A1 (en) 2023-07-31 2026-03-12 Sixpeaks Bio Ag Antibody conjugates and fusion proteins
WO2025183966A1 (en) 2024-02-28 2025-09-04 Versanis Bio, Inc. Actrii antibodies with extended half life

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2993053A1 (en) 2009-04-27 2010-11-04 Novartis Ag Antagonistic activin receptor iib (actriib) antibodies for increasing muscle growth
JP5912078B2 (ja) * 2009-06-08 2016-04-27 アクセルロン ファーマ， インコーポレイテッド 熱発生性脂肪細胞を増加させるための方法
EP3290439B1 (en) * 2009-06-12 2020-09-02 Acceleron Pharma Inc. Truncated actriib-fc fusion proteins
JP6211767B2 (ja) * 2009-09-09 2017-10-11 アクセルロン ファーマ， インコーポレイテッド ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用
DK2726099T3 (en) * 2011-07-01 2018-11-05 Novartis Ag Method of treating metabolic disorders
EA201492282A1 (ru) * 2012-06-11 2015-07-30 Амген Инк. Антагонистические антигенсвязывающие белки к двум рецепторам и их применение
CA2969800A1 (en) * 2014-12-08 2016-06-16 Novartis Ag Myostatin or activin antagonists for the treatment of sarcopenia
WO2016205370A1 (en) * 2015-06-15 2016-12-22 Santa Maria Biotherapeutics, Inc. Methods of using activin receptor iib-based proteins
CN109069467B (zh) * 2015-11-11 2022-11-04 诺华股份有限公司 肌生成抑制蛋白拮抗剂的用途、含有它们的组合及其用途

Also Published As

Publication number Publication date
MX2019007581A (es) 2019-09-04
JP7280825B2 (ja) 2023-05-24
RU2019119375A (ru) 2021-01-22
JP2020511422A (ja) 2020-04-16
PT3558361T (pt) 2025-10-28
EP4659804A2 (en) 2025-12-10
ES3048908T3 (en) 2025-12-12
FI3558361T3 (fi) 2025-11-11
TW201825120A (zh) 2018-07-16
EP3558361A1 (en) 2019-10-30
CN110087684A (zh) 2019-08-02
MX2024001135A (es) 2024-02-27
TWI848773B (zh) 2024-07-11
CL2019001683A1 (es) 2019-09-13
KR20190097138A (ko) 2019-08-20
US20210363263A1 (en) 2021-11-25
HRP20251338T1 (hr) 2025-12-19
WO2018116201A1 (en) 2018-06-28
CN110087684B (zh) 2023-12-01
BR112019012661A2 (pt) 2020-01-28
SI3558361T1 (sl) 2026-01-30
EP4659804A3 (en) 2026-02-25
LT3558361T (lt) 2025-11-25
AU2017380844A1 (en) 2019-05-16
RU2019119375A3 (ar) 2021-01-29
CN118105478A (zh) 2024-05-31
US20190345251A1 (en) 2019-11-14
IL327136A (en) 2026-05-01
IL267471A (en) 2019-08-29
AU2017380844B2 (en) 2024-12-19
JP2023052026A (ja) 2023-04-11
TWI812606B (zh) 2023-08-21
DK3558361T3 (da) 2025-11-03
KR20240147705A (ko) 2024-10-08
EP3558361B1 (en) 2025-08-20
IL267471B1 (en) 2026-04-01
JP7843223B2 (ja) 2026-04-09
TW202417043A (zh) 2024-05-01
RU2765288C2 (ru) 2022-01-28
PL3558361T3 (pl) 2025-12-08
PH12019501026A1 (en) 2019-12-16
RS67393B1 (sr) 2025-11-28
CA3042965A1 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
MX2024001135A (es) Antagonistas de miostatina, activina o receptor de activina para el uso en el tratamiento de la obesidad y afecciones relacionadas.
CY1119987T1 (el) Παραγωγα εξενδινης-4 ως διττοι αγωνιστες glp1/γλυκαγονης
BR112015018104A2 (pt) polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições
PH12019501216A1 (en) New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
MX2016013244A (es) Derivados de exendina-4 como agonistas peptidicos duales del receptor de glp-1/glucagon.
MX2016013248A (es) Agonistas duales del receptor de glp-1/glucagon derivados de exendina-4.
TW201613633A (en) Exendin-4 derivatives as selective glucagon receptor agonists
MX2015008079A (es) Agonista duales de glp1/gip o trigonales de glp1/gip/glucagon.
MX2019006427A (es) Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip.
EA201590294A1 (ru) Аналоги глюкагона
BR112016029713A8 (pt) uso de uma carboximetilcelulose reticulada e uso de um agente gelificante
PH12016501619A1 (en) Substituted fused heterocycles as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
PH12014501336A1 (en) Glucagon analogues
AR098738A1 (es) Análogos del péptido exendina-4 no acilados
CL2014002556A1 (es) Compuestos derivados de ácidos indaniloxidihidrobenzofuranilacéticos, agonistas del receptor gpr40; composiicon farmaceutica; y su uso en el tratamiento de enfermedades o afecciones como diabetes, resistencia a la insulina, obesidad, entre otras.
BR112017004949A2 (pt) receptor do antígeno quimérico, polinucleotídeo, vetor, célula, e, composição farmacêutica.
MX2017012864A (es) Analogo acilado del glucagon.
EA201791611A1 (ru) Лечение пациентов детского возраста с сахарным диабетом 2 типа с помощью ликсисенатида
EP4406957A3 (en) Aryl receptor modulators and methods of making and using the same
MX379289B (es) Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.
PH12017500084A1 (en) Vitamin b2 and its use
BR112017005986A2 (pt) composições e métodos de uso para o tratamento de distúrbios metabólicos
TR201908045T4 (tr) Peynir Altı Suyu Protein Miselleri Ve Pektin Karışımının Vücut Ağırlığını Kontrol Amaçlı Kullanımı.